Risks of combining immunosuppressive and biological treatments in inflammatory bowel disease.

Suppr

超能文献

作者信息

Roblin Xavier, Phelip Jean Marc

出版信息

Arch Intern Med. 2008 Mar 24;168(6):667; author reply 667-8. doi: 10.1001/archinte.168.6.667.

DOI:10.1001/archinte.168.6.667

PMID:18362263

Abstract

摘要

相似文献

Risks of combining immunosuppressive and biological treatments in inflammatory bowel disease.

Arch Intern Med. 2008 Mar 24;168(6):667; author reply 667-8. doi: 10.1001/archinte.168.6.667.

Methotrexate in inflammatory bowel disease.

Gastroenterol Clin North Am. 2004 Jun;33(2):407-20, xi. doi: 10.1016/j.gtc.2004.03.001.

Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

Gut. 2007 Sep;56(9):1181-3. doi: 10.1136/gut.2006.115980.

[Must immunomodulators be added to biological treatment in inflammatory bowel disease?].

Gastroenterol Hepatol. 2010 Jan;33(1):43-53. doi: 10.1016/j.gastrohep.2009.03.008. Epub 2009 Jul 18.

Medical therapy of IBD in 2009.

Med Health R I. 2009 Mar;92(3):78-81.

[Benefits and risks of immunosuppression in chronic inflammatory bowel diseases].

Dtsch Med Wochenschr. 2008 Sep;133(38):1917-21. doi: 10.1055/s-0028-1085577. Epub 2008 Sep 10.

[Biologic therapy for inflammatory bowel diseases].

Rev Gastroenterol Mex. 2006 Aug;71 Suppl 1:91-4.

Immunosuppresive therapy for inflammatory bowel disease.

Rev Esp Enferm Dig. 2003 Jul;95(7):456-8, 453-5.

Long-term treatment of Crohn's disease with methotrexate, or, why's a nice drug like you still a wannabe in the treatment of inflammatory bowel disease?

Am J Gastroenterol. 2000 Jul;95(7):1619-20. doi: 10.1111/j.1572-0241.2000.02182.x.

Immunosuppression in inflammatory bowel disease: traditional, biological or both?

Curr Opin Gastroenterol. 2009 Jul;25(4):323-8. doi: 10.1097/MOG.0b013e32832c073a.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验